

Sanofi  
Form 6-K  
December 31, 2013  
o

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

---

**For the month of December 2013**

**Commission File Number: 001-31368**

**SANOFI**

(Translation of registrant's name into English)

**54, rue La Boétie, 75008 Paris, FRANCE**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Edgar Filing: Sanofi - Form 6-K

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If  Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

## Edgar Filing: Sanofi - Form 6-K

In November and December 2013, Sanofi issued the statements attached hereto as Exhibits 99.1 to 99.7 which are incorporated herein by reference.

### Exhibit List

Exhibit No.	Description
Exhibit 99.1	Press release dated, November 22, 2013: Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Exhibit 99.2	Press release dated, December 3, 2013: Sanofi Announces New Phase 3 Results for Investigational New Insulin U300
Exhibit 99.3	Press release dated, December 5, 2013: New Data Support Flexibility in Timing of Administration for Sanofi's Lyxumia®
Exhibit 99.4	Press release dated, December 11, 2013: FDA Grants Priority Review for Genzyme's Cerdelga (eliglustat), an Investigational Oral Therapy for Gaucher Disease
Exhibit 99.5	Press release dated, December 12, 2013: Merial Receives EMA approval for Broadline for Broad Spectrum Parasite Treatment and Prevention in Cats
Exhibit 99.6	Press release dated, December 19, 2013: Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program
Exhibit 99.7	Press release dated, December 30, 2013: Genzyme Receives Complete Response Letter from FDA on Lemtrada (alemtuzumab) Application

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: December 31, 2013

SANOFI

By

/S/ John Felitti

Name:

Title:

John Felitti

Associate Vice President,

Corporate Law, Financial & Securities Law

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated, November 22, 2013: Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Exhibit 99.2	Press release dated, December 3, 2013: Sanofi Announces New Phase 3 Results for Investigational New Insulin U300
Exhibit 99.3	Press release dated, December 5, 2013: New Data Support Flexibility in Timing of Administration for Sanofi's Lyxumia®
Exhibit 99.4	Press release dated, December 11, 2013: FDA Grants Priority Review for Genzyme's Cerdelga (eliglustat), an Investigational Oral Therapy for Gaucher Disease
Exhibit 99.5	Press release dated, December 12, 2013: Merial Receives EMA approval for Broadline for Broad Spectrum Parasite Treatment and Prevention in Cats
Exhibit 99.6	Press release dated, December 19, 2013: Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program
Exhibit 99.7	Press release dated, December 30, 2013: Genzyme Receives Complete Response Letter from FDA on Lemtrada (alemtuzumab) Application